Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Nucera Discusses the Role of RNA in Thyroid Cancer
October 31st 2014, 11:23am
Annual Meeting of the American Thyroid Association
Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer
Disease-Related Variables Predictive of Outcomes With Sorafenib in DTC
October 31st 2014, 10:32am
Annual Meeting of the American Thyroid Association
Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.
Afatinib Extends OS by Approximately 1 Year in Subgroup of NSCLC
October 31st 2014, 8:14am
Chicago Multidisciplinary Symposium in Thoracic Oncology
First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.
Dr. Dadu on Reducing MTC-Related Diarrhea With CASAD
October 31st 2014, 8:10am
Annual Meeting of the American Thyroid Association
Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.
Dr. Govindan on the Potential for Alectinib
October 31st 2014, 6:42am
Chicago Multidisciplinary Symposium in Thoracic Oncology
Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.
PD-1 Immunotherapies Induce Painless Thyroiditis in Patients With Metastatic Malignancies
October 31st 2014, 6:32am
Annual Meeting of the American Thyroid Association
Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies
Post-Operative Radiation Therapy Improves Overall Survival in NSCLC Patients
October 31st 2014, 6:32am
Chicago Multidisciplinary Symposium in Thoracic Oncology
Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.
Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance Mutation
October 31st 2014, 5:01am
Chicago Multidisciplinary Symposium in Thoracic Oncology
D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.
Dr. Cohen Discusses the Challenges of Treating Medullary Thyroid Cancer
October 30th 2014, 2:53pm
Annual Meeting of the American Thyroid Association
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating Medullary Thyroid Cancer (MTC).
Molecular Profiling Reveals Potential Targets in SCLC, Lung NETs
October 30th 2014, 2:30pm
Chicago Multidisciplinary Symposium in Thoracic Oncology
Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).
PCP Knowledge Gap Could Affect Lung Cancer Screening Implementation
October 30th 2014, 1:31pm
Chicago Multidisciplinary Symposium in Thoracic Oncology
A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.
Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6
October 30th 2014, 12:06pm
Chicago Multidisciplinary Symposium in Thoracic Oncology
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.
Reducing Lung Biopsies May Cut Costs, Improve Patient Outcomes
October 30th 2014, 11:11am
Chicago Multidisciplinary Symposium in Thoracic Oncology
Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.
Dr. Gandara Discusses the Future of Clinical Trial Designs
October 30th 2014, 11:07am
Chicago Multidisciplinary Symposium in Thoracic Oncology
David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.
Molecular Diagnostics Focus on Thyroid Nodule Classification
October 30th 2014, 8:06am
Annual Meeting of the American Thyroid Association
New data being presented at the 84th Annual Meeting of the American Thyroid Association show promise for two molecular tests that help identify indeterminate thyroid nodules as either benign or malignant.
Dr. Metz Discusses Using a Multidisciplinary Approach When Treating NETs
October 13th 2014, 8:56am
David C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).
Somatic Mutations in the ATRX Gene Reported for the First Time in Pheochromocytomas/ Paragangliomas
October 13th 2014, 7:58am
Somatic mutations in the ATRX gene are observed in about 13% of pheochromocytomas/paragangliomas, the first such report of somatic ATRX mutations in these tumors.
Dr. Kulke on Unanswered Questions Surrounding the Treatment of NETs
October 13th 2014, 7:21am
Matthew Kulke, MD, comments on some unanswered questions surrounding the treatment of neuroendocrine tumors (NETs).
CDKN1B Mutation May Be Linked to Worse Survival in GEP NETs
October 13th 2014, 6:16am
Low nuclear expression of CDKN1B, a cyclin-dependent kinase inhibitor gene that encodes p27, in gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) appears to be associated with a worse prognosis.
Few Agents Better Than Somatostatin Analogs for Symptom Control in Carcinoid Syndrome
October 11th 2014, 3:04pm
Somatostatin analogs remain the mainstay of medical therapy for symptom control in patients with carcinoid syndrome.